Get the Stockscreener App
7.86
4.94%
0.37
Astria Therapeutics Inc stock is traded at $7.86, with a volume of 443.75K.
It is up +4.94% in the last 24 hours and down -12.08% over the past month.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
See More
Previous Close:
$7.49
Open:
$7.58
24h Volume:
443.75K
Relative Volume:
1.46
Market Cap:
$443.57M
Revenue:
-
Net Income/Loss:
$-72.89M
P/E Ratio:
-3.2479
EPS:
-2.42
Net Cash Flow:
$-68.47M
1W Performance:
+6.07%
1M Performance:
-12.08%
6M Performance:
-32.71%
1Y Performance:
-39.68%
1-Day Range:
$7.51
$7.95
1-Week Range:
$7.34
$7.95
52-Week Range:
$7.16
$16.90
Astria Therapeutics Inc Stock (ATXS) Company Profile
Name
Astria Therapeutics Inc
Sector
Industry
Phone
617-349-1971
Address
22 BOSTON WHARF ROAD, BOSTON
Compare ATXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
7.86 | 443.57M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-24 | Initiated | TD Cowen | Buy |
| Mar-28-23 | Initiated | Evercore ISI | Outperform |
Astria Therapeutics Inc Stock (ATXS) Latest News
Astria Therapeutics (NASDAQ:ATXS) Earns Outperform Rating from Analysts at JMP Securities - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Upgraded by Citizens Jmp to Strong-Buy Rating - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Up 25.7% in January - MarketBeat
Astria wins new Outperform rating at JMP on drug technology - MSN
Astria stock wins new Outperform at JMP (ATXS:NASDAQ) - Seeking Alpha
JMP Securities Initiates Astria Therapeutics at Outperform -January 31, 2025 at 08:17 am EST - Marketscreener.com
JMP Securities starts Astria Therapeutics stock with $26 target By Investing.com - Investing.com Canada
JMP Securities starts Astria Therapeutics stock at Market Outperform By Investing.com - Investing.com UK
JPMorgan Chase & Co. Increases Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
What To Expect From Astria Therapeutics In Q4 - RTTNews
Astria Therapeutics (NASDAQ:ATXS) Earns “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Reaffirms "Buy" Rating for Astria Therapeutics (NASDAQ:ATXS) - MarketBeat
H.C. Wainwright sets $16 target on Astria Therapeutics stock - MSN
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis - Business Wire
Astria Therapeutics Launches Phase 1a Trial of Novel Atopic Dermatitis Treatment STAR-0310 - StockTitan
Where are the Opportunities in (ATXS) - Stock Traders Daily
Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Large Increase in Short Interest - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.60 Consensus Price Target from Brokerages - Defense World
HC Wainwright Reaffirms “Buy” Rating for Astria Therapeutics (NASDAQ:ATXS) - Defense World
Barclays PLC Has $1.02 Million Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics (NASDAQ:ATXS) Receives Buy Rating from HC Wainwright - MarketBeat
Astria Therapeutics plans phase 3 trial for HAE drug - Investing.com
Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE - Business Wire
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Buy" from Analysts - MarketBeat
Jane Street Group LLC Has $404,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Jane Street Group LLC Cuts Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Astria Therapeutics Awards Stock Options to New Employees Under Inducement Plan - StockTitan
Geode Capital Management LLC Trims Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Geode Capital Management LLC Has $10.50 Million Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Barclays PLC Boosts Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Large Decrease in Short Interest - MarketBeat
(ATXS) Investment Analysis - Stock Traders Daily
Astria Therapeutics (NASDAQ:ATXS) Stock Price Down 3.4%Here's What Happened - MarketBeat
State Street Corp Reduces Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
State Street Corp Sells 495,436 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $25.60 - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes $613,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $613,000 in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics expands stock incentive plan - Investing.com
Astria Therapeutics Expands Stock Incentive Plan - TipRanks
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.60 Consensus PT from Brokerages - MarketBeat
Is Astria Therapeutics (ATXS) Stock Outpacing Its Medical Peers This Year? - MSN
Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Grows By 8.6% - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Has $3.46 Million Stock Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
ATXSAstria Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Astria’s OX40 antagonist gains US IND clearance for atopic dermatitis - BioWorld Online
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE - Business Wire
FDA clears Astria Therapeutics' new AD drug for trial By Investing.com - Investing.com Canada
Astria's Navenibart Shows Remarkable 95% HAE Attack Reduction in Phase 1b/2 Trial Results - StockTitan
Astria Therapeutics Inc Stock (ATXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Astria Therapeutics Inc Stock (ATXS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morabito Christopher | Chief Medical Officer |
Apr 01 '24 |
Sale |
13.59 |
10,000 |
135,939 |
0 |
3.95%
2.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):